Keywords: cancer immunotherapy; PD-1; CTLA-4; checkpoint blockade; MDSCs
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ABVD; doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP; bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; FDG; [18F]-fludeoxyglucose; GHSG; German Hodgkin Study Group; MOPP; nitrogen mustard, vincristine,
Keywords: Gy; gray; Ab; antibody; TGF-β; transforming growth factor-β; TNF; tumor necrosis factor; SASP; senescence-associated secretory phenotype; MCP-1; monocyte chemoattractant protein-1; MHC; major histocompatibility complex; DAMP; damage-associated molecular
Keywords: HNSCC; Immunotherapy; CTLA-4; PD-1; Cetuximab; Vaccine; Chimeric antigen receptor;
Keywords: Immunotherapy; NSCLC; Immune checkpoint blockade; CTLA-4; PD-1; PD-L1
Keywords: AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: 17-AAG; 17-(Allylamino)-17-demethoxygeldanamycin; 17-DMAG; 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; AKT; v-akt murine thymoma viral oncogene homolog; APC; antigen presenting cell; ATM; Ataxia telangiectasia mutated; ATR; Ataxia telangiectasia
Keywords: Radiation; Immunotherapy; Dose; Fractionation; MHC-I; major histocompatibility class I; ICAM-1; intercellular adhesion molecules-1; CEA; carcinoembryonic antigen; CTL; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; gp 100; glycopr
Keywords: 5-ALA; 5-aminolevulinic acid; 5-FU; 5-fluorouracil; APC; antigen presenting cell; BCC; basal cell carcinoma; CAP; cold atmospheric plasma; CM; cutaneous malignant melanoma; CNP; cerium oxide nanoparticle; CNT; carbon nanotube; COX-2; cyclooxygenase II; CP
Keywords: Breast cancer; HER-2-negative; Resistance; Biologic targeted agent; Combination therapy; ABC; advanced breast cancer; AE; adverse event; AI; aromatase inhibitor; AKT; protein kinase; BC; breast cancer; CDK; cyclin-dependent kinase; CT; chemotherapy; CTLA;
Keywords: Breast cancer; Immune system; Biomarkers; Immunotherapies; Immune checkpoint blockade; Tumor vaccines; ADCC; antibody dependent cellular cytotoxicity; BiTES; bispecific single chain monoclonal antibodies; CAR; T cells engineered to express artificial chim
Keywords: Advanced melanoma; CTLA-4; Immunotherapy; Long-term survival; PD-1; Targeted therapy;
Keywords: Persistent Viral Infection; Immune Exhaustion; Co-Inhibitory Molecules; T-cell Immunity; Bim; BCL-2 interacting mediator of cell death; HBV; hepatitis B virus; HCV; hepatitis C virus; IFN; interferon; IL; interleukin; iMATE; intrahepatic myeloid cell aggr
Keywords: CRH; corticotropin-releasing hormone; CTLA4; cytotoxic T lymphocyte antigen 4; IFN-γ; interferon gamma; DC; dendritic cell; E2; estradiol-17β; ER; estrogen receptor; hCG; human chronic gonadotropin; HPA; hypothalamic-pituitary-adrenal; NF-κB; nuclear f
Keywords: AE; adverse effect; APC; antigen-presenting cells; CI; confidence interval; CP; carboplatin and paclitaxel; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; cuSCC; cutaneous squamous cell carcinoma; FDA; Food and Drug Administ
Keywords: APC(s); antigen presentation cell(s); ARG1; arginase-1; Breg(s); regulatory B (cells); CAF(s); cancer-associated fibroblast(s); CD; cluster of differentiation protein; CD40L; cluster of differentiation protein 40 ligand; C/EBP; CAAT/enhancer binding prote
Keywords: Head and neck cancer; Immunotherapy; Monoclonal antibody; STAT; CTLA-4; PD-1; HPV; p53; Cytokine;
Keywords: DC; dendritic cell; TAA; tumour associated antigen; NC; nucleocapsid; MA; matrix; CA; capsid; RRE; rev response element; cppt; central DNA flap; WPRE; woodchuck post-transcriptional response element; TCR; T cell receptor; pMHC; peptide-MHC complex; Th;
Keywords: Bladder cancer; Checkpoint inhibitors; 5H1; PD-1; PD-L1
Keywords: AAV; adeno-associated viruses; Ad6; adenovirus serotype 6; ABCB5Â +; ATP-binding cassette sub-family B member 5; ALDH; aldehyde dehydrogenase; AML; acute myeloid leukemia; APCs; antigen presenting cells; B7.1; (CD80) cluster of differentiation 80; BCG; Ba
T-cell receptor gene therapy - ready to go viral?
Keywords: T-cell receptor; Gene therapy; Cancer; Immunotherapy; T cell; ACT; adoptive cell therapy; allo-SCT; allogeneic stem cell transplantation; APC; antigen-presenting cell; BLAST; basic local alignment search tool; CAR; chimeric antigen receptor; CTL; cytotoxi
Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
Keywords: alopecia areata; anti-programmed cell death protein-1; drug adverse event; immune related; lung cancer; melanoma; nivolumab; AA; alopecia areata; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; ICI; immune checkpoint inhibitors; PD-1; programmed
Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications
Keywords: Abscopal effect; Cancer stem cell; Checkpoint inhibitor; Cryoimmunotherapy; Neoantigen; Renal cell carcinoma; Tumor microenvironment; Tumor vaccine; PD-1; programmed death 1; TIL; tumor-infiltrating lymphocytes; ECM; extracellular matrix; TAA; tumor-assoc
A novel mouse model for tracking the fate of CXCR5-expressing T cells
Keywords: Follicular helper T cells; CXCR5; Memory T cells; Humoral immunity; GC; Germinal center; Tfh; Follicular helper T; OVA; Ovalbumin; CXC-R5; C-X-C chemokine receptor type 5; CCR7; C-C chemokine receptor type 7; ICOS; Inducible costimulator; PD-1; Programmed
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Keywords: PD-L1; Programmed cell death-ligand 1; PD-1; programmed cell death-1; CBIS; cell-based immunization and screening; SCC; squamous cell carcinoma; ACC; adenoid cystic carcinoma; MEC; mucoepidermoid carcinoma; CTLA-4; cytotoxic T-lymphocyte-associated antige
HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers
Keywords: Human immunodeficiency virus; Human Papillomavirus; Head and neck cancer; PD-1; PD-L1; Immune checkpoint blockade; Antigen processing machinery;
CXCR5+ CD8 T cells displayed higher activation potential despite high PD-1 expression, in tumor-involved lymph nodes from patients with thyroid cancer
Keywords: CXCR5â¯+â¯CD8+ T cells; PD-1; Thyroid cancer;
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Keywords: CTL; cytotoxic T lymphocytes; EGFR; epidermal growth factor receptor; FACS; fluorescence-activated cell sorting; HCC; hepatocellular carcinomas; Inr; initiator; PD-1; programmed cell death protein-1; PD-L1; programmed cell death-ligand; T-ALL; T cell acut
Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer
Keywords: Anaplastic thyroid cancer; Natural killer cell; PD-1; Tim-3;
Expression of B7-H2 on CD8+ T cells in colorectal cancer microenvironment and its clinical significance
Keywords: MHC; major histocompatibility complex; TCR; T cell receptor; CTLA-4; cytotoxic T lymphocyte associated antigen-4; PD-1; programmed deth-1; PD-L1; programmed deth-1 ligand; TILs; tumor infiltrating lymphocytes; SPF; specific pathogen free; B7-H2; T cells;
Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC)
Keywords: OSCC; Oral squamous cell carcinoma; TSCC; Tongue squamous cell carcinoma; HNSCC; Head and neck squamous cell carcinoma; iCIKs; Improving cytokine-induced killer cells; TILs; Tumour-infiltrating lymphocytes; PBMCs; Peripheral blood mononuclear cells; IRB;
PD-L1 expression in large cell neuroendocrine carcinoma of the lung
Keywords: Lung cancer; Neuroendocrine carcinoma; LCNEC; PD-L1; PD-1;
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
Keywords: PD-1; PD-L1; CTLA-4; DNA methylation; Lower-grade glioma; Prognosis;
Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases
Keywords: aa; Amino acids; A region; Acidic region of IL-2Rβ; AKT; Protein kinase B; AA; Alopecia Areata; CTLA-4; Cytotoxic T lymphocyte antigen-4; cDNA; Complementary DNA; Foxp3; Forkhead box P3; GVHD; Chronic graft-versus-host disease; HCV; Hepatitis C virus; hd
Combining chemotherapy with PD-1 blockade in NSCLC
Keywords: NSCLC; non-small cell lung cancer; PT-DC; platinum-doublet chemotherapy; ORR; objective response rate; PD-1; programmed cell death-1; PD-L1; programmed death ligand-1; CTLA-4; cytotoxic T-lymphocyte antigen-4; DC; dendritic cell; TME; tumor microenvironme
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Keywords: Pembrolizumab; Melanoma; PD-1; PD-L1;
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide
Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1
Keywords: Oropharyngeal cancer; Human papillomavirus; PD-1; Tim-3; Tumor-infiltrating lymphocytes;
Notch signaling pathway dampens tumor-infiltrating CD8+ T cells activity in patients with colorectal carcinoma
Keywords: CCK-8; cell counting kit-8; CTLA-4; cytotoxic T-lymphocyte associated protein-4; DAPT; N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenyl glycinet-butyl ester; FBS; fetal bovine serum; GM-CSF; granulocyte-macrophage colony stimulating factor; IFN-γ; interf
The Role of PD-1 Positivity in the Tumour Nest on Clinical Outcome in Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy
Keywords: Nephroureterectomy; PD-1; progression; survival; upper tract urothelial carcinoma;
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Keywords: CI; confidence interval; DCR; disease control rate; DOC; docetaxel; EMA; European Medicines Agency; FDA; US Food and Drug Administration; HR; hazard ratio; ITT; intent to treat; NSCLC; non-small cell lung cancer; OR; odds ratio; ORR; objective response ra
Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer
Keywords: Ovarian cancer; Mismatch repair deficiency; Microsatellite instability; PD-1; PDL-1;
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Keywords: AE; adverse event; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; HR; hazar
A new enzyme immunoassay for the determination of highly sialylated and fucosylated human α1-acid glycoprotein as a biomarker of tumorigenesis
Keywords: AGP; α1-acid glycoprotein; AS-AGP; asialo-α1-acid glycoprotein; EIA; enzyme immunoassay; AAL; Aleuria aurantia lectin; Con A; concanavalin A; BSA; bovine serum albumin; PD-1; programmed death-1; Fuc; fucose; Gal; galactose; GlcNAc; N-acetylglucosamine;
Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteins
Keywords: Regulatory CD4 T cells; HIV-1; HIV-1 integration; HIV-1 mRNA; CTLA-4; PD-1; GARP;
Increased PD-1+CD154+ Tfh cells are possibly the most important functional subset of PD-1+ T follicular helper cells in adult patients with minimal change disease
Keywords: Tfh cells; Minimal change disease; PD-1; CD154;
Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma
Keywords: Cancer; PD-1; Immunotherapy; Inflammation; T cells; Esophageal adenocarcinoma;
Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer
Keywords: PD-1; IDO; Breast cancer; Tumor microenvironment (TME); Tumor-draining lymph nodes (TDLNs); TCGA dataset; PD-1; programmed cell death protein 1; IDO; indoleamine 2,3-dioxygenase; TME; tumor microenvironment; TDLNs; tumor-draining lymph nodes; APCs; antige
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Keywords: Cancer immunotherapy; Immune checkpoint blockade; CTLA-4; PD-1; PD-L1;
Bacterially activated B-cells drive T cell differentiation towards Tr1 through PD-1/PD-L1 expression
Keywords: Hfstim; Helicobacter felis -stimulated; Hfstim- IL-10+ B; Helicobacter felis-stimulated IL-10- producing B cells; Hfstim- IL-10-B; Helicobacter felis-stimulated IL-10- nonproducing B cells; Breg; regulatory B cells; PD-1; programmed death 1; PD-L1; pr